Although Cvac is regarded as the most important ovarian cancer...

Although Cvac is regarded as the most important ovarian cancer treatment currently being developed we know that it's going to be a long road to commercialisation.

A number of milestones have to be reached along the way and the most important company objectives for Cvac in the next six months or so appear to be;

1. The attaining of Orphan Drug Status, and

2. The commencement of Phase IIb trials.

What are your thoughts on the upside potential of the sp if the above milestones are reached before the end of the calendar year??


Stagman